May 23, 2018 / 1:17 PM / 7 months ago

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 (Reuters) - Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment’s efficacy.

Esperion’s shares plunged some 30 percent on May 2 after analysts questioned the drug’s safety and effectiveness despite late-stage results showing that the treatment had met the main study goal.

In the new study, the treatment, bempedoic acid, met the main goal of reduction in low-density lipoprotein cholesterol levels when compared with a placebo.

The study results also showed that adverse muscle-related side effects were lower in patients taking Esperion’s treatment compared with those on a placebo.

Esperion’s shares rose nearly 3 percent in premarket trading. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below